bioAffinity Technologies, Inc. - 10-Q Filing
bioAffinity Technologies reports Q3 2026 financial results including revenue from histology service fees and CyPathLung services.
Tickers: $BIAF
Read the full article at SEC EDGAR
Part of the story bioAffinity Technologies, Inc. - 10-Q Filing (3 articles)